Morepen Lab gets USFDA clearance for its bulk drug Montelukast Sodium

20 Dec 2017 Evaluate

Morepen Laboratories has received approval from United States Food and Drug Administration (USFDA) for Montelukast Sodium, a bulk drug / API to sell in the US market. This gives Morepen an entry into the Rs 2000 crore US market for Montelukast. The first commercial orders for the bulk drug are expected in Q2 of FY 2018-19.

Morepen is a well-known pharma company having well equipped Research & Development Centre and is all set to seize the Generic revolution in pharma industry, by filing multiple DMFs and COS for new APIs.

Morepen Laboratories Share Price

42.42 -1.03 (-2.37%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×